Skip to content

The effect of personalised 3D printed metamaterial insoles on plantar pressures in adults at risk of diabetes-related foot wounds.

Evaluation of the effect of 3D printed functionally graded metamaterial insoles on plantar pressures in adults at risk of diabetes-related foot ulceration: A within-subjects crossover study.

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12626000508370
Enrollment
18
Registered
2026-04-23
Start date
2026-04-27
Completion date
2026-06-29
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Diabetes-related foot ulceration is a debilitating condition that arises in part due to high mechanical pressures acting on the underside of the foot. Preventative offloading treatments including medical grade footwear and personalised insoles are often used to reduce these pressures in an effort to prevent ulceration in people who are determined to be high risk. The research team have developed an approach to 3D print accessible and low-cost personalised metamaterial insoles with functionally graded stiffness that varies across the device. These insoles could potentially be used to enhance the effectiveness of pressure redistribution and prevention of diabetes related foot ulceration. This within-subjects repeated-measures crossover study in people at risk of diabetes related foot ulceration will compare the immediate effects on plantar pressures in medical grade footwear with personalised 3D printed metamaterial offloading insoles produced using automated design algorithms compared to medical grade footwear with the current standard of care personalised foam insoles. The results of this study will provide insight to the most suitable design algorithms for functionally graded insoles as part of preventative treatment. The findings of this study in people at risk of diabetes related foot ulceration will inform larger future studies evaluating the longer-term effects of the insoles in people at risk of diabetes-related foot ulceration.

Interventions

Current Australian and international guidelines recommend the use of medical-grade footwear and personalised insoles to prevent diabetes-related foot ulceration in individuals at risk, particularly those with foot deformities or pre-ulcerative lesions. This study will evaluate whether functionally graded 3D printed insoles that have material stiffness personalised according to plantar pressure measurements are as effective as the current standard of care in reducing plantar pressures in people

Current Australian and international guidelines recommend the use of medical-grade footwear and personalised insoles to prevent diabetes-related foot ulceration in individuals at risk, particularly those with foot deformities or pre-ulcerative lesions. This study will evaluate whether functionally graded 3D printed insoles that have material stiffness personalised according to plantar pressure measurements are as effective as the current standard of care in reducing plantar pressures in people at risk of diabetes-related foot ulceration. This study includes several arms. As a cross-over study, each participant will experience each intervention and control arm. Participants will be invited to attend two appointments. Each appointment is anticipated to take approximately 60 minutes. At an initial appointment, following screening for inclusion/exclusion criteria, plantar pressures will be measured barefoot and when wearing the issued medical grade trial footwear. This plantar pressure data will be used to design insoles using an automated algorithm. Specifically, the plantar pressure will be used to define the stiffness of the metamaterial across the insole. This study has two intervention arms and two control arms. Intervention arm 1 will be a 3D printed metamaterial insole comprising metamaterials of uniform stiffness that approximates low density EVA foam (the current standard of care). Intervention arm 2 will be a 3D printed metamaterial insole comprising metamaterials with graded stiffness that ranges from low density EVA foam (at hardest) through to Poron (blue medical), a material commonly used as a component of insoles designed to reduce plantar pressures in clinical practice (at softest). The stiffness of the insole will be set based upon the peak plantar pressure at the corresponding part of the foot. Between these thresholds, the stiffness will be interpolated. The design algorithm parameters will define a graduated transition zone, whereby at sites of the foot with low pressures (less than 50 kPa), the insole will have properties approximating low density EVA, and at sites of high pressures (greater than 200 kPa), the insole will have properties approximating Poron (blue medical). Prior engineering work has benchmarked the stiffness of the metamaterial to that of materials that are commonly used in insole and footwear manufacture (EVA foam and Poron). Following the initial appointment, each of the intervention and control insoles will be designed and fabricated for the individual. The second appointment is anticipated to occur 2-4 weeks following the initial appointment. At the second appointment, each of the intervention and control insoles will be fit to the standardised medical grade footwear in a randomised order. The participant will be blinded to the difference between the different insole conditions. Primary outcome measures (plantar pressure in device during gait) will be recorded after a brief period of acclimatisation (at least 2 minutes). The participant will walk straight for approximately 10m at a self-selected speed while data is recorded to provide at least 12 steps of data for the foot. Walking speed during the trial will be self-selected for the first trial and measured, to ensure each subsequent trial is within ten percent of this speed. Trials outside of this will be discarded and repeated to ensure walking speed is kept consistent during testing of each condition. Three trials will be completed for each study arm. There will be a washout and rest period between study arms of at least 3 minutes. As an immediate effects study design, insoles will not be worn for an extended period nor taken by the participants, and no assessment of adherence will be performed. Should any intervention be discontinued prior to data collection (e.g. due to discomfort reported by participant), this will be reported. Each intervention and the control insole will be designed, manufactured, and fit by a podiatrist at a university research facility.

Sponsors

Queensland University of Technology
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Prevention
Masking
Blinded (masking used) (Subject)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Over 18 years old Available to attend follow up data collection appointment 2-4 weeks following initial data collection Able to walk for ten minutes duration without the use of assistive devices (e.g. walking stick or frame) Diagnosis of diabetes Have an International Working Group for the Diabetic Foot (IWGDF) risk classification of moderate to high risk with foot deformity or a buildup of hard skin (callous) or a previous history of diabetes related foot ulceration.

Exclusion criteria

Under 18 year of age Unable to walk for ten minutes unassisted History of foot or lower limb amputation History of Charcot neuroarthropathy Active diabetes-related foot ulceration End-stage renal disease History of falls in the past 12 months

Outcome results

None listed

Source: ANZCTR · Data processed: May 7, 2026